Financial Analysis: MetaWorks Platforms (OTCMKTS:MWRK) versus OptimizeRx (NASDAQ:OPRX)

OptimizeRx (NASDAQ:OPRX) and MetaWorks Platforms (OTCMKTS:MWRK) are both small-cap computer and technology companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, risk, valuation and institutional ownership.

Profitability

This table compares OptimizeRx and MetaWorks Platforms’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OptimizeRx	-27.41%	-4.92%	-3.41%
MetaWorks Platforms	N/A	-249.65%	-157.91%

Valuation and Earnings

This table compares OptimizeRx and MetaWorks Platforms”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OptimizeRx	$71.52 million	1.49	-$17.57 million	($1.33)	-4.35
MetaWorks Platforms	$410,000.00	3.38	-$5.65 million	($0.08)	-0.18

MetaWorks Platforms has lower revenue, but higher earnings than OptimizeRx. OptimizeRx is trading at a lower price-to-earnings ratio than MetaWorks Platforms, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations for OptimizeRx and MetaWorks Platforms, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OptimizeRx	0	3	6	0	2.67
MetaWorks Platforms	0	1	0	0	2.00

OptimizeRx presently has a consensus price target of $9.06, suggesting a potential upside of 56.79%. Given OptimizeRx’s stronger consensus rating and higher possible upside, research analysts plainly believe OptimizeRx is more favorable than MetaWorks Platforms.

Risk and Volatility

OptimizeRx has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500. Comparatively, MetaWorks Platforms has a beta of 1.22, indicating that its share price is 22% more volatile than the S&P 500.

Insider and Institutional Ownership

76.5% of OptimizeRx shares are held by institutional investors. Comparatively, 16.1% of MetaWorks Platforms shares are held by institutional investors. 6.1% of OptimizeRx shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

OptimizeRx beats MetaWorks Platforms on 9 of the 14 factors compared between the two stocks.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events. The company was founded in 2006 and is based in Waltham, Massachusetts.

About MetaWorks Platforms

MetaWorks Platforms, Inc. provides blockchain and Web3 development platform. It offers turnkey set of services for companies to develop and integrate blockchain and cryptocurrency technologies into their business operations. The company provides business development and technical services; blockchain and technology program management services; customer development services; business launch services; and post-business launch support services. The company was formerly known as CurrencyWorks Inc. and changed its name to MetaWorks Platforms, Inc. in August 2022. MetaWorks Platforms, Inc. was incorporated in 2010 and is based in Fairfield, California.